RenDu Bio announced that its controlling shareholder, Jinliang Ju, and others will transfer approximately 8.52 million shares to Nanjing Haijing Pharmaceutical for about 516 million yuan. Following this transaction, Haijing Pharmaceutical will become the new controlling shareholder, and Xiantao Zhang will be the new actual controller. This change is expected to enhance the company's operational and management capabilities, integrate its existing in-vitro diagnostic product resources, and create a comprehensive, integrated solution from diagnosis to treatment. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
RANK_REASON Significant change in controlling shareholder and strategic integration plans for a publicly traded company. [lever_c_demoted from significant: ic=1 ai=0.1]